Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5276226 | 0.83 | S1PR1 (0.49) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5276231 | 0.83 | S1PR1 (0.49) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4341940 | 0.81 | PPARG (0.41) | PPARGPPARASOAT2SOAT1FAAH | |
| SCHEMBL4341938 | 0.81 | PPARG (0.41) | PPARGPPARASOAT2SOAT1FAAH | |
| SCHEMBL16878592 | 0.79 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL16878593 | 0.79 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL21457933 | 0.79 | SMYD2 (0.34) | CYP3A4 | |
| SCHEMBL21457932 | 0.79 | SMYD2 (0.34) | CYP3A4 | |
| SCHEMBL21457931 | 0.79 | SMYD2 (0.34) | CYP3A4 | |
| SCHEMBL21411327 | 0.79 | SGPL1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | CYP1A2 4521/4885CYP3A4 4033/4885CYP2D6 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.